Stockwinners Market Radar for May 18, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:40 EDT Cathie Wood's ARK Investment bought 4.7M shares of Ginkgo Bioworks today

18:40 EDT Frontier Communications plans to exceed fiber build target in 2022 - Frontier Communications plans to exceed its target of 1 million fiber locations in 2022, according to CFO Scott Beasley speaking at the MoffettNathanson Media Communications Summit. Beasley announced that Frontier plans to accelerate the fiber build, and now expects to exceed its 2022 build target of 1 million fiber locations by an additional 100,000-200,000 locations. Frontier continues to expect a cost of $900-1000 per passing for its Wave 2 build plan. The recent closing of $1.2B in additional debt puts Frontier in position to accelerate its fiber build. Pro-forma for the debt offering, the company maintains its net leverage ratio of 2.5x and has $4B of liquidity, which enables the company to fund the fiber build with cash on hand for approximately the next two years.

18:30 EDT Cactus director Semple sells 20,000 class A shares - In a regulatory filing, Cactus director Alan Semple disclosed the sale of 20,000 class A common shares of the company on May 16 at a price of $48.84 per share.

18:28 EDT Group 1 Automotive increases quarterly dividend 2.8% to 37c per share - Group 1 declared a cash dividend of 37c per share for Q1, an increase of 2.8%, or 1c per share, from 4Q21. The dividend will be payable on June 15 to stockholders of record as of June 1.

18:27 EDT Group 1 Automotive increases stock repurchase authorization to $250M - Group 1 Automotive increased its common stock repurchase authorization by $175M to $250M. Year-to-date repurchase activity is 796,060 shares of common stock at an average price of $179.72 for a total of $143.1M, which represents 4.6% of Group 1's outstanding share count at January 1. The company expects that any repurchase of shares will be funded by cash from operations. Repurchased shares will be held in treasury.

18:22 EDT Dish enters deal to sell AT&T Internet services - AT&T (T) and DISH (DISH) have entered into a distribution agreement that will allow DISH to offer AT&T Internet services, including AT&T Fiber with Hyper-Gig speeds, to prospective, new and existing DISH customers starting today. Reference Link

18:09 EDT Babcock & Wilcox awarded $68M installation services contract - Babcock & Wilcox Construction Company has been awarded a contract for approximately $68M to provide construction and installation services for a power plant maintenance project in North America.

17:40 EDT Four Corners Property Trust acquires NextCare Primary Care property for $1.8M - Four Corners Property Trust announced the acquisition of a NextCare Primary Care property for $1.8M. The property is located in a strong retail corridor in Arizona and is corporate-operated under a net lease with approximately 7 years of term remaining. The transaction was priced at a 6.4% going-in cash capitalization rate, exclusive of transaction costs.

17:28 EDT Cisco says order cancellations still at low levels - Says has implemented non-cancellation policy on orders.

17:21 EDT Kraft Heinz CEO sells $11.5M in common stock - In a regulatory filing, Kraft Heinz disclosed that its CEO Miguel Patricio sold 260K share of common stock on May 16th in a total transaction size of $11.5M.

17:19 EDT Stellus Capital CEO buys $126K in common stock - In a regulatory filing, Stellus Capital disclosed that its CEO Robert Ladd bought 9.8K shares of common stock on May 16th in a total transaction size of $126.4K.

17:04 EDT Denbury, Nutrien enter agreement for transportation and storage of CO2 - Denbury Carbon Solutions, a wholly owned subsidiary of Denbury (DEN) and PCS Nitrogen Fertilizer, a wholly owned subsidiary of Nutrien (NTR) announced that the parties have reached a term-sheet agreement under which Denbury would transport and store carbon dioxide captured from Nutrien's potential new clean ammonia project at its Geismar, Louisiana location. Nutrien is evaluating its Geismar, Louisiana, ammonia facilities as a potential site for new ammonia production to serve growing demand in agriculture, industrial and emerging energy markets. Nutrien is progressing the proposed project to the front-end engineering design phase, with a final investment decision expected to follow in 2023 and, if approved, full production by 2027. The new plant is expected to have annual production capacity of 1.2M metric tons of clean ammonia, with approximately 1.8M metric tons per year of CO2 to be captured. Under the terms of the agreement, Nutrien would pay Denbury for the transportation and sequestration of the associated CO2 into Denbury's secure underground containment sites. The initial term of the agreement is 12 years, with up to two extension terms of five years each.

17:01 EDT Adamis names David Marguglio president, CEO - Adamis Pharmaceuticals Corporation announced a leadership transition plan to support its efforts to unlock long-term growth and value creation opportunities. David J. Marguglio, Co-Founder and Chief Business Officer, has been appointed President and Chief Executive Officer, effective immediately. Dennis J. Carlo, Ph.D., has retired from the President and Chief Executive Officer roles, and stepped down from the Board of Directors, effective immediately. Marguglio will continue his director role, and a search has commenced to identify a highly qualified and independent director to fill the vacancy resulting from Dr. Carlo's retirement from the Company. Mr. Marguglio commented, "Having led the company to three FDA product approvals, I want to thank Dennis for his many years of service and tireless effort to position Adamis as an innovator in the biopharmaceutical sector. As I step into the CEO role, my goal is to build on the Company's foundation. I believe advancing and broadening our product pipeline through new collaborations and partnerships, combined with growing sales from SYMJEPI and ZIMHI, which was recently launched, will create significant long-term value for patients, providers and stockholders alike."

16:47 EDT AppLovin CLO sells $3.39M in common stock - In a regulatory filing, AppLovin disclosed that its Chief Legal Officer Victoria Valenzuela sold 90K shares of common stock on May 16th in a total transaction size of $3.39M.

16:32 EDT Under Armour CEO Patrik Frisk to step down, Colin Browne named interim CEO - Under Armour announced that Patrik Frisk will step down as President and CEO and as a member of the Board of Directors, effective June 1. The board has initiated a comprehensive internal and external search process to identify a permanent President and CEO. Until a successor is named, the board has appointed Colin Browne, the company's COO, as interim President and CEO, effective June 1. To support the transition, Frisk will remain with Under Armour as an advisor through September 1. Since joining the company in 2016, Browne modernized Under Armour's digital go-to-market strategy and direct-to-consumer model and transformed its supply chain organization, leading to significant margin improvement and operating efficiency. Browne has held the role of COO since 2020 and oversees supply chain, global planning, sustainability, information technology, enterprise data management, commercial optimization, go-to-market strategy, and distribution capabilities. Browne has been an integral part of the company's successful transformation, and his leadership has been critical to navigating global supply challenges caused by the pandemic.

16:31 EDT Under Armour CEO Patrik Frisk to step down, Colin Browne named interim CEO

16:20 EDT Ocwen appoints Sean O'Neil CFO - Ocwen Financial Corporation announced the appointment of Sean O'Neil as executive VP and CFO, effective June 13. He joins Ocwen from Bayview Asset Management, where he served as the company's CFO since 2015.

16:17 EDT Cisco reports Q3 adjusted gross margin 65.3% - On a non-GAAP basis, total gross margin, product gross margin, and service gross margin were 65.3%, 64.1%, and 68.9%, respectively, as compared with 66.0%, 64.9%, and 68.7%, respectively, in the third quarter of fiscal 2021. Total gross margins by geographic segment were: 64.8% for the Americas, 65.9% for EMEA and 66.4% for APJC. On a GAAP basis, total gross margin, product gross margin, and service gross margin were 63.3%, 61.8%, and 67.3%, respectively, as compared with 63.9%, 62.6%, and 67.4%, respectively, in the third quarter of fiscal 2021.

16:16 EDT Agios Pharmaceuticals chief scientific officer Bruce Car to resign - In a regulatory filing, Agios Pharmaceuticals disclosed that on May 15, Bruce Car, Ph.D. notified the company of his decision to resign as chief scientific officer of the company, effective July 31.

16:15 EDT Chart Industries closes $4M CSC Cryogenic Service Center acquisition - Chart Industries completed the acquisition of CSC Cryogenic Service Center AB, a Swedish company for approximately $4M. The company said, "CSC brings a strong service footprint in the Nordic Region with many overlapping customers to Chart, allowing us to broaden our service and repair presence geographically. Our strong original equipment ("OE") installed base and continued OE forecasted growth in the Nordic region will benefit from this localized support. Not only does this expand our geographic footprint, it broadens our repair and service capabilities for mobile equipment, in particular trailers, as well as ISO containers, stationary and transportable tanks, pumps, flowmeters and LNG fueling stations. In particular, we have a number of customers looking to us for exclusive full care service and maintenance agreements in this region as well as installation & commissioning capabilities for LNG stations. CSC also brings strong relationships with key customers in the marine industry, and utilizing our global commercial team, we expect to realize synergies from the CSC offering with both companies' marine customers."

16:14 EDT Globus Maritime to purchase two bulk carriers for $70.3M - Globus Maritime announced that it has signed two contracts for the construction and purchase of two fuel efficient bulk carriers of about 64,000 DWT each. The sister ships will be built at Nantong COSCO KHI Ship Engineering in China with the first one scheduled to be delivered during the third quarter of 2024 and the second one scheduled during the fourth quarter of 2024. The total consideration for the construction of both vessels is approximately $70.3M, which the company intends to finance, like the newbuilding announced on May 10, with a combination of debt and cash on hand, although the company will continue to explore the best options at the relevant financing time.

16:11 EDT HF Foods Group receives additional noncompliance letter from Nasdaq - HF Foods Group announced that the company received a notification letter from the Listing Qualifications Department of Nasdaq stating that the company is not in compliance with Nasdaq Listing Rule 5250, which requires timely filing of all required periodic reports with the Securities and Exchange Commission, or SEC. The Nasdaq notification letter was sent as a result of the company's delay in filing its quarterly report on Form 10-Q for the quarter ended March 31. The Nasdaq notification letter has no immediate effect on the listing or trading of the Company's common stock on the Nasdaq Capital Market. The company filed a Notification of Late Filing on Form 12b-25 on May 11. In the Form 12b-25, the company indicated that the filing of the Form 10-Q would be delayed as a result of an ongoing review of accounting issues relating to the Company's business combination with B&R Global on November 4, 2019, in response to a SEC comment letter.

16:06 EDT HealthStream acquires remaining stake in CloudCME for $4.08M - HealthStream "announced the completion of its acquisition of the remaining equity interest of CloudCME, a Nashville-based healthcare technology company with a nationwide customer base. HealthStream originally invested in CloudCME in March 2019 when it purchased approximately 20 percent of the equity interest in the company. With its acquisition today of the remaining equity interest in CloudCME, HealthStream gains a best-in-class SaaS-based application for managing all aspects of continuing education within a healthcare organization. The purchase price paid for the outstanding equity of CloudCME that HealthStream did not previously own was approximately $4.08 million in cash, subject to post-closing working capital adjustment, and $4.08 million in shares of HealthStream's common stock issued through a private placement."

16:02 EDT United Fire Group increases quarterly dividend 6.7% to 16c per share - The board of directors of United Fire Group approved a dividend increase of 6.7% over the previous quarterly dividend and declared a common stock quarterly cash dividend of 16c per share. This dividend will be payable June 17 to shareholders of record as of June 3.

16:01 EDT Enanta reports topline data from RSVP study of EDP-938 - Enanta Pharmaceuticals reported topline results for RSVP, its Phase 2b study evaluating EDP-938, a potent N-protein inhibitor, in otherwise healthy adults with community-acquired RSV. In this low-risk patient population which had mild, self-resolving upper respiratory tract infection, EDP-938 did not meet the primary endpoint of reduction in total symptom score compared to placebo, or the secondary antiviral endpoints. However, a statistically significant difference in the number of subjects achieving undetectable RSV RNA at the end of treatment at Day 5 was observed with EDP-938 compared to placebo. Further, EDP-938 demonstrated a favorable safety profile, consistent with that observed in approximately 500 subjects exposed to date. Enanta continues to evaluate EDP-938 in high-risk populations in ongoing and planned clinical studies, including pediatric patients, adult hematopoietic cell transplant recipients, and a high-risk adult population, all of which have the most significant unmet need. "While RSVP did not meet the study endpoints, we are pleased to observe a statistically significant difference in the number of subjects achieving undetectable RSV RNA at the end of treatment with EDP-938, making this the only study that has demonstrated a statistically significant antiviral effect in an otherwise healthy adult population with community-acquired RSV. The effect on RSV RNA viral load is consistent with EDP-938's mechanism of action of inhibiting viral replication," said Jay R. Luly, President and Chief Executive Officer of Enanta Pharmaceuticals. "Although patients were treated within 48 hours of symptom onset, a key observation in this study was that the viral load and symptoms had already peaked and were declining at the time of the first dose, indicating RSV infection resolves quickly in this otherwise healthy population."

15:29 EDT NY AG launches probes into social media companies following Buffalo shooting - New York Attorney General Letitia James announced that her office is launching investigations into social media companies in connection with the terror attack in Buffalo that claimed 10 lives and wounded three individuals. The investigations will look into the social media companies and other online resources that the shooter used to discuss and amplify his intentions and acts to carry out this attack. Specifically, the investigations will focus on those platforms that may have been used to stream, promote, or plan the event, including but not limited to Twitch, which is owned by Amazon (AMZN), 4chan, 8chan, and Discord. "The terror attack in Buffalo has once again revealed the depths and danger of the online forums that spread and promote hate," said Attorney General James. "The fact that an individual can post detailed plans to commit such an act of hate without consequence, and then stream it for the world to see is bone-chilling and unfathomable. As we continue to mourn and honor the lives that were stolen, we are taking serious action to investigate these companies for their roles in this attack. Time and time again, we have seen the real-world devastation that is borne of these dangerous and hateful platforms, and we are doing everything in our power to shine a spotlight on this alarming behavior and take action to ensure it never happens again." Other publicly traded social media companies include Meta (FB), Snap (SNAP), and Twitter (TWTR). Reference Link

14:13 EDT Square acquires GoParrot digital ordering and marketing platform for restaurants - Square, part of Block, announced that it has acquired GoParrot, a digital ordering and marketing platform for restaurants. "GoParrot enables restaurants to connect more easily and directly with customers through powerful omnichannel software. As a long-time Square partner, GoParrot's products already integrate with Square's ecosystem of solutions. With GoParrot, Square sellers can offer an exceptional customer experience with a customizable white-label app that merchants can design to be unique to their brand. Through the app, buyers can seamlessly place orders while also viewing top selling items and deal popups for enhanced personalization. Restaurants can also increase buyer retention by offering consumers an easy way to track loyalty rewards right from their mobile device," the company stated. GoParrot's solutions are currently available in the U.S., Canada, Australia, and the UK, Square notes. Reference Link

13:04 EDT United applies to launch nonstop service between Washington, D.C., Cape Town - United Airlines announced it has filed an application with the U.S. Department of Transportation for three weekly nonstop flights between Washington, D.C. and Cape Town, South Africa. If approved, United's flights will become the first nonstop service ever between Washington D.C. and South Africa's legislative capital, Cape Town. The company said, "This long-overdue route will benefit important government-to-government connections and increase communication and commerce with a region that has strong cultural ties to South Africa." United's proposed service would begin Nov. 17, 2022, and operate on 787-9 aircraft.

12:52 EDT Costamare terminates six shipbuilding contracts for newbuild vessels - In a regulatory filing yesterday, Costamare indicated that on May 16, the company served a notice of termination for six shipbuilding contracts which it had entered into with a shipyard for the construction of two container vessels of 12,690 TEU each and four container vessels of 15,000 each.

12:25 EDT Fang receives NYSE Regulation notice on commencement of delisting - Fang Holdings announced that it received a notice from the NYSE Regulation staff regarding the commencement of delisting proceedings of the Company's American depositary shares on the basis that the ADSs are not suitable for listing due to the Company's failure to file with the Securities and Exchange Commission its annual report on Form 20-F for the year ended December 31, 2020 and current report on Form 6-K for the half year ended June 30, 2021 by May 17, 2022, which is the maximum time allowed under Section 802.01E of the NYSE's Listed Company Manual. The NYSE suspended the trading in the ADSs on May 18, 2022. The Company has until June 2, 2022 to submit a written request to appeal the NYSE Regulation staff's delisting decision.

12:11 EDT Musk calls ESG 'outrageous scam' after S&P removes Tesla - After Standard and Poor's removed Tesla from its S&P 500 ESG Index, Elon Musk tweeted, "ESG is an outrageous scam! Shame on @SPGlobal. Exxon is rated top ten best in world for environment, social & governance (ESG) by S&P 500, while Tesla didn't make the list! ESG is a scam. It has been weaponized by phony social justice warriors."

12:02 EDT Renewable Energy enters strategic partnership with CFN, Pacific Pride - Renewable Energy Group has entered into strategic collaboration agreements with CFN and Pacific Pride, two cardlock fueling networks, to provide cleaner fuels through their branded cardlock networks. Partnering REG's portfolio of bio-based diesel with CFN and Pacific Pride's vast network of cardlocks will allow the companies to play a critical role in furthering the utilization of cleaner fuels by fleets across North America, REG said in a statement.

12:00 EDT Triumph Group falls -19.7% - Triumph Group is down -19.7%, or -$4.32 to $17.56.

12:00 EDT MagnaChip rises 12.9% - MagnaChip is up 12.9%, or $2.24 to $19.57.

12:00 EDT Sunlands Online rises 16.5% - Sunlands Online is up 16.5%, or 65c to $4.59.

11:21 EDT TJX expects to repurchase $2.25B-$2.5B of TJX stock this FY

11:10 EDT TJX views Homegoods as strongly positioned in retail environment

11:04 EDT TJX's Q1 comp sales were a bit lighter than plans, says CEO - Comments taken from Q1 earnings conference call.

10:33 EDT Vertex Pharmaceuticals appoints Suketu Upadhyay to board of directors - Vertex Pharmaceuticals announced that Suketu Upadhyay has been elected to its board of directors as an independent director. He is currently the Executive Vice President and CFO of Zimmer Biomet.

10:15 EDT Corvia adds Repay as processing partner - Corvia announced it has added Repay Holdings Corporation. The relationship will provide additional fuel for Corvia's aggressive growth trajectory by enhancing merchant and partner servicing and support in traditional retail and specialty e-commerce business segments.

10:00 EDT Big Lots falls -14.9% - Big Lots is down -14.9%, or -$4.89 to $27.97.

10:00 EDT Target falls -25.9% - Target is down -25.9%, or -$55.78 to $159.50.

10:00 EDT Container Store rises 9.7% - Container Store is up 9.7%, or 70c to $7.91.

09:53 EDT MagnaChip strength attributed to Korean-language report of takeover bid - Strength in shares of MagnaChip Semiconductor (MX) is being attributed to a Korean-language report published by Maeil Business Newspaper that claims LX Group and private equity firm Carlyle (CG) jointly submitted a letter of intent for an acquisition of the chipmaker. Previously, on April 26, Korea Economic Daily's Jun-ho Cha reported that South Korea's LX Group, a split-off from LG Group, was looking to acquire Magnachip and would be making its interest official by submitting a letter of intent. In early trading, MagnaChip shares are up $2.37, or 14%, to $19.70. Reference Link

09:49 EDT Amazon announces Fire 7, Fire 7 Kids tablets - Amazon announced the next-generation Fire 7 and Fire 7 Kids tablets, which the company said is "bringing more speed, performance, and value to the company's most affordable tablet." The new Fire 7 and Fire 7 Kids offer double the RAM and 40% longer battery life for hours of entertainment, video calling, and fun for every member of the family, while the compact size makes it an on-the-go companion. The Fire 7 Kids includes a kid-proof protective case, a one-year subscription of Amazon Kids+, and a two-year worry-free guarantee. Both tablets are available to order today and will begin shipping on June 29. Fire 7 starts at only $59.99 and is available today for pre-order at www.amazon.com/fire7. The all-new Fire 7 comes in black, denim, and rose colors, with coordinating covers for $28.99, and will begin shipping June 29. Fire 7 Kids is available for pre-order today starting at $109.99, and for the first time, it offers 16GB or 32GB storage options.

09:47 EDT Doximity falls -14.7% - Doximity is down -14.7%, or -$4.97 to $28.80.

09:47 EDT Triumph Group falls -26.2% - Triumph Group is down -26.2%, or -$5.73 to $16.15.

09:47 EDT TJX rises 10.4% - TJX is up 10.4%, or $5.84 to $62.03.

09:46 EDT VEDU Stock trading halted, volatility trading pause

09:35 EDT Black Rifle Coffee appoints Chris Clark as CTO - Black Rifle Coffee Company has appointed Chris Clark as its Chief Technology Officer. A twenty-five year technology professional with deep retail experience, most recently as Chief Information Officer of Levi Strauss & Co., Clark expands the BRCC executive team and joins a group of experienced leaders who are executing on BRCC's omnichannel approach to grow and scale the company.

09:32 EDT Lowe's says gross margin pressure will shift into Q2 - Says delay of Spring weather has negatively impacted seasonal categories and DIY sales. Says encouraged by improved sales trends in May. Says increased uncertainty in macro environment. Says has seen higher demand across seasonal categories now that the weather has broke in the North. Says confident will deliver first half results in line with full-year guidance. Says gross margin pressure will shift into Q2. Sees first half gross margin up slightly. Comments taken from Q1 earnings conference call.

09:24 EDT Vitru receives final approval for business combination with Unicesumar - Vitru announced that the antitrust approval of its proposed business combination with CESUMAR - Centro de Ensino Superior de Maringa Ltda, or "Unicesumar," has become final and definitive. On April 29, 2022 Vitru had announced that its proposed business combination with Unicesumar had received a recommendation of approval of the General Superintendence of CADE. The decision was published in the Official Gazette on May 2, 2022. According to Law No. 12,529/2011, there was an additional 15-day waiting period following publication for CADE's decision to become final. This additional waiting period expired on May 17, 2022, and the decision is now final and definitive. The closing of the business combination is expected to take place on May 20, 2022, following which we will begin to integrate the activities of Unicesumar with those of Vitru. Through the proposed business combination, Vitru - through its wholly-owned subsidiary Vitru Brasil Empreendimentos, Participacoes e Comercio S.A. - will own 100% of the total share capital of Unicesumar.

09:18 EDT Illumina and Allegheny Health collaborate to assess in-house genomic profiling - Illumina and Allegheny Health Network - AHN -, an integrated health system serving the Western Pennsylvania area, announced a collaboration to evaluate the impact of in-house comprehensive genomic profiling - CGP - to enhance patient care. The collaboration will assess the value of in-house testing for both tissue and blood samples, versus sending those samples externally, and whether this approach may benefit cancer patients and the broader healthcare system. The collaboration will also work to identify instances where blood-based testing is most beneficial, depending on cancer stages and types. The initiative is part of AHN Cancer Institute's plan to help improve the cancer care pathway through its newly established AHN Clinical Genomics Laboratory in Pittsburgh. The project commenced in 2022 and is slated for one year, with the potential to expand this clinical research in the future.

09:11 EDT Clarus Therapeutics announces issuance of patent covering JATENZO - Clarus Therapeutics announced that the United States Patent and Trademark Office has issued a new patent for claims that cover Clarus' oral testosterone replacement product, JATENZO. Patent No. 11,331,325 entitled "Pharmaceutical Delivery Systems for Hydrophobic Drugs and Compositions Comprising Same" covers Clarus' commercialized product, JATENZO. The new patent will expire in January 2027. "This new patent further reinforces our already impressive intellectual property portfolio for JATENZO," said Dr. Robert Dudley, President and Chief Executive Officer of Clarus. "We believe that having eight patents listed in FDA's Orange Book underscores our multi-pronged strategy for success in the marketplace by protecting this important asset."

09:10 EDT Euroseas announces new charter for two teu feeder containerships - Euroseas announced a new charter for two newbuilding fuel efficient 2,800 teu feeder containerships currently under construction. Specifically: M/V GREGOS, a modern eco-design 2,800 teu scheduled to be delivered at the end of the first quarter of 2023, entered into a time charter contract for a period of between a minimum of thirty-six and a maximum of forty months at the option of the charterer, at a gross daily rate of $48,000. The new charter will commence in March 2023, once delivered. M/V TERATAKI, a modern eco-design 2,800 teu scheduled to be delivered at the end of the second quarter of 2023, entered into a time charter contract for a period of between a minimum of thirty-six and a maximum of forty months at the option of the charterer, at a gross daily rate of $48,000. The new charter will commence in June 2023, once delivered. Aristides Pittas, Chairman and CEO of Euroseas commented: "We are very pleased to announce three-year charters for the first two of our fuel efficient 2,800 teu feeder containerships under construction, M/V GREGOS and M/V TERATAKI, at a gross daily rate of $48,000 each. The new charters will commence upon delivery of the vessels in March 2023 and June 2023, respectively. Over the period of the charters, the two vessels are expected to contribute in excess of $85m of EBITDA fully repaying our cost to build them in just about 3 years. After these charters, our charter coverage for 2023 increases to about 76% and for 2024 to almost 55%."

09:09 EDT Borqs Technologies wins solar plus energy storage contract in Hawaii - Borqs Technologies announced that its solar plus energy storage systems subsidiary Holu Hou Energy, HHE, has partnered with a State Agency, the Hawaii Green Energy Infrastructure Authority, HGIA, and won a contract to supply solar plus energy storage systems to Kunia Village affordable housing community on the island of Oahu. This is a milestone in the Company's strategy in transforming into the renewable energy industry, specifically serving the Multi-Unit Residential Buildings, MURB, market. Kunia Village includes 135 housing units, a church, an administration building, a former store, and a gymnasium where the residents have the opportunity to reduce their electricity bill by enrolling into usage of the electricity generated by the project under a leasing arrangement set up by HHE and HGIA. Under the arrangement, HHE and HGIA have created a 3rd party lease program leveraging HGIA's Green Energy Market Securitization financing product, whereby the community members can enroll in the energy savings program. Each unit will have solar generation as well as a HoluPower energy storage system. The design and installation will be performed by HHE, an approved contractor for HGIA financed projects.

09:07 EDT GoDaddy and Inky enter email security partnership - GoDaddy announced its partnership with Inky, a cloud-based communication security platform. This partnership brings Inky's anti-phishing and email assistant offering to customers of GoDaddy's Advanced Email Security solution for Microsoft 365. The new partnership replaces the prior advanced secure email gateway solution with Inky's detection capabilities and dynamic banners for GoDaddy customers.

09:06 EDT AgriFORCE Growing Systems completes acquisition of IP from Manna Nutritional - AgriFORCE Growing Systems announced it has completed the previously announced acquisition of the intellectual property of Manna Nutritional Group. The IP encompasses patent-pending technologies to naturally process and convert grain, pulses and root vegetables, resulting in low-starch, low-sugar, high-protein, fiber-rich baking flour products, as well as a wide range of breakfast cereals, juices, natural sweeteners and baking enhancers. The core process is covered under a pending patent application in the U.S. and key international markets. Independent lab testing indicates that MNG's soft white wheat baking flour contains over 30 times the fiber, 3 times the protein, and more than 80% less starch than conventional flour without compromising taste, texture and quality. The Company's initial focus is on wheat, in which the flour has applications for baked goods, breads and snacks. As further announced earlier this year, the Company is on track to pilot test its first branded product in the specialty flour category under the brand un(Think) Foods with businesses and consumers later this year. The un(Think) brand aims to evolve the way people think about their favorite foods and create a new standard for nutrition. The Company has also completed the engineering work for small-scale manufacturing and has begun preparation for planned production in Saskatchewan, Canada, with initial operations expected to commence in second half of 2022.

09:05 EDT Brivo announces partnership with Doyle Security Systems - Brivo, a provider in cloud-based access control and smart building technologies that entered into a definitive merger agreement with Crown PropTech Acquisitions, announced a partnership with Doyle Security Systems, the largest family-owned provider of residential and commercial security, fire and medical monitoring systems in New York State and northwest Pennsylvania. Through the partnership, Doyle will expand its product offering to include Brivo Access, Brivo's signature cloud-based access control product, offering cloud-based access control to its customers.

09:04 EDT Identiv collaborates with Wiliot on Battery-Assisted Pixel cold chain solution - Identiv announced its collaboration with Wiliot on the first to market Battery-Assisted Pixel - BAP -. The business card-sized BAP is the first Bluetooth Low Energy - BLE - asset management and cold chain scalable solution on the market. The multi-use Pixel aims to provide traceability, authentication, temperature, and capacitive sensing along with location and time stamp capabilities. BAP tags continuously broadcast secure sensing and ID information that any Bluetooth standard device can read with Wiliot integrated software. Tags can also be placed on food packaging, crates, or other consumer items during transport to ensure the temperature stays within predetermined parameters for safe transit. Wiliot's main offering, Battery-Free IoT Pixels, are postage-stamp-sized, passive, lower-cost tags that communicate securely over BLE and harvest their energy from Bluetooth and RFID frequencies. They are not limited by battery life. The tags attach to any product or packaging to sense a range of physical and environmental data fed into the Wiliot Cloud, where machine learning algorithms translate data into actionable insights for businesses across a range of industries.

09:04 EDT D-Orbit signs strategic agreement with Astralintu Space Technologies - D-Orbit announced that it has signed an agreement with Astralintu Space Technologies, a leading Ecuadorian space logistics company. Under the terms of the agreement, Astralintu will represent D-Orbit for customers in Latin America and the Caribbean, helping D-Orbit expand its commercial presence in the regions. "Countries across the world are participating in the new space economy. With this agreement with Astralintu Space, we are continuing to expand D-Orbit's global footprint," said Renato Panesi, D-Orbit's Chief Commercial Officer. "We look forward to working closely with Astralintu to capture growth opportunities and support the development of a dynamic space industry in Latin America and the Caribbean." Astralintu is a New Space company with capabilities in CubeSat manufacturing and payload integration, and space mission management based in Quito, Ecuador. The company focuses on providing in-orbit and ground station services to new and existing actors in Latin America and the rest of the world. Their S-band ground station will be integrated within the network of Aurora, D-Orbit's proprietary cloud-based mission control software suite, increasing its future global coverage. This integration was recently highlighted in a joint Workshop between the companies during the 2022 Global Conference on Space for Emerging Countries in Quito, Ecuador. As previously announced on January 27, 2022, D-Orbit has entered into a business combination agreement among Breeze Holdings Acquisition Corp

09:02 EDT Target to raise prices 'surgically,' says CEO

08:58 EDT Prescience Point urges MiMedx to confirm letters of concern from other holders - Prescience Point Capital Management, a research-focused, catalyst-driven investment firm that beneficially owns approximately 6.7% of the outstanding common stock of MiMedx Group, issued the following statement, in part, : "In recent press releases and letters, MiMedx has misleadingly portrayed Prescience Point as a lone disgruntled shareholder. However, from what we understand, several other large MiMedx shareholders, representing millions of MDXG shares, have sent correspondence to the Company outlining similar concerns to ours. With an important vote coming up at the company's annual meeting of shareholders on June 7, 2022, we believe it is imperative that shareholders know the truth. As such, we call upon the Board and management to publicly confirm that they have received letters of concern from other large shareholders in recent weeks," stated Eiad Asbahi, Founder and Managing Partner of Prescience Point. Prescience Point reiterated its intention to WITHHOLD its votes against two members of MDXG's Board of Directors, Phyllis Gardner and James Bierman, who are up for election at the company's annual meeting, and to vote AGAINST approval of the executive compensation package.

08:49 EDT SouFun trading halted, news pending

08:46 EDT Solitario provides update on Lik, Florida Canyon projects - Solitario Zinc is pleased to update exploration and other associated activities on its Lik and Florida Canyon high-grade zinc projects and joint venture plans for the remainder of 2022. Lik Zinc Project: The Lik project hosts an Indicated Resource of 17.6 million tonnes grading 8.07% zinc, 2.68% lead and 50.1 grams per tonne silver and an additional 2.8 million tonnes of Inferred Resource grading 8.64% zinc, 2.73% lead and 38.9 grams per tonne silver. The project is situated approximately 17 kilometers northwest of Teck's operating Red Dog mine, one of the world's largest, highest grade and lowest cost zinc mines. Solitario and its joint venture partner, Teck American Incorporated, a wholly owned subsidiary of Teck Resources Limited recently approved a jointly funded budget for the 2022 Lik work program that consists of exploration drilling and gravity geophysics. Three core holes totaling 650 meters are planned at Lik during the summer field season to test for resource extensions on the northeast and northwest margins of the currently defined resource footprint, with the third hole on the southern margin. Of note, one of the planned drill holes will also test the potential for stacked mineralization. The Induced Polarization geophysical survey conducted on the Lik property in 2021 suggested that the mineralized horizon hosting the Lik deposit flattens to the west and could be at drillable depths in a valley floor situated approximately three kilometers to the west. The planned gravity geophysical survey will test for gravity anomalies potentially associated with buried zinc mineralization. On May 12, 2022, Teck announced the formation of its Zinc Satellite initiative to surface value from Teck's portfolio of world-class zinc development assets. The Lik Zinc Project is one, among five projects selected for Teck's value creating initiative. View Teck's press release in its entirety here. Teck is currently the world's largest net zinc miner based on zinc production from Red Dog in Alaska and Antamina in Peru. Florida Canyon Zinc Project: The Florida Canyon project hosts an Indicated Resource of 2.4 million tonnes grading 10.62% zinc, 1.33% lead and 15.0 grams per tonne silver and an additional 14.9 million tonnes of Inferred Resource grading 9.63% zinc, 1/26% lead and 11.3 grams per tonne silver. Solitario's joint venture partner, Nexa Resources, is focusing its 2022 work program in three critical areas to advance the project: The first is to finish an access road to several near-by communities that currently have no vehicle access. This effort is part of the joint venture's social commitment to people and communities in the vicinity of the Florida Canyon project area. Several kilometers of new road have been completed, as well as significant upgrading of previously pioneered road. The road is expected to be completed before the end of the year. The second significant 2022 program is completion of a comprehensive metallurgical testing program focusing on sulfide dominant mineralization. Nearly five tonnes of previously drilled mineralized core will be subjected to a variety of tests to better estimate zinc, lead and silver recoveries, as well as the grade and quality of Florida Canyon concentrates that would be deliverable to smelters. Finally, drill hole permitting is well underway to significantly expand the area permitted for drilling activities for 2023 and beyond. The permit application will enlarge the area permitted for drilling by approximately 500 percent. Over 80 new drill hole sites are planned in areas to the south, east and southeast of the Florida Canyon deposit. Multiple drill holes can be completed from each site. These drill sites are located on trend with the Florida Canyon deposit to the south and a parallel trend a couple kilometers to the east. Both of these multi-kilometer trends have undrilled high-grade zinc mineralization at surface comparable to the surface mineralization at Florida Canyon.

08:43 EDT RiceBran announces capacity expansion at MGI Grain facility - RiceBran Technologies announced the initiation of a significant capacity expansion of the Company's MGI Grain Incorporated facility in East Grand Forks, Minnesota. The expansion is expected to double the capacity of the pearling mill, enabling RiceBran to meet growing demand for North American-sourced, grain-based ingredients and with a minimal capital investment and a limited increase in labor. The project will replace one of the mill's main grain de-hullers with a new de-huller/pearler; more than doubling the plant's production capacity. In addition to the new huller, MGI will support increased throughput and quality with the addition of a color sorter, as well as enhancements to the mill's grain receiving, cleaning and conveyance systems. The project, which is being executed by a trusted contractor and RiceBran's own internal engineering team, is deployed in a manner that minimizes disruption to the mill's daily operations. The investments, which totaled less than half-a-million dollars, are expected to be completed in mid-summer 2022.

08:38 EDT Target sees profit performance beginning to improve in 2H - Doesn't expect environment to be "anything close to normal" in 2H.

08:37 EDT Target sees FY22 share repurchases lower than FY21

08:36 EDT Celularity announces $30M private placement - Celularity announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor for the purchase and sale of 4,054,055 shares of its Class A common stock at a purchase price of $7.40 per share and warrants to purchase 4,054,055 shares of its Class A common stock at an exercise price of $8.25 per share in a private placement priced at-the-market under Nasdaq rules, resulting in total gross proceeds of approximately $30.0 million before deducting placement agent commissions and other estimated offering expenses. The warrants will be exercisable immediately after the date of issuance and will expire five years following the initial issuance date. The closing of the offering and sale of the Securities is expected to occur on or about May 20, 2022, subject to the satisfaction of customary closing conditions. A.G.P./Alliance Global Partners is acting as the sole placement agent for the offering.

08:34 EDT Veru appoints Batten as EVP, Head of US Infectious Disease Franchise - Veru announced the appointment of Joel Batten as Executive Vice President, EVP, and Head of its U.S. Infectious Disease Franchise effective May 23, 2022. Most recently Batten has been the Head of the Respiratory Syncytial Virus, RSV, Franchise at Sobi North America.

08:34 EDT Genius Brands signs 20-year deal with Marvel Studies to license 'Stan Lee' - "Stan Lee Universe," Genius Brands International's (GNUS) "Genius Brands" controlled venture with POW! Entertainment, has signed a 20-year deal to license the name and likeness of Stan Lee to Marvel Studios (DIS) for future feature films and television productions, as well as use in Disney theme parks and experiences worldwide. "We are proud to be the stewards of the incredibly valuable rights to Stan Lee's name, likeness, merchandise, and intellectual property brand," said Andy Heyward, Chairman & CEO of Genius Brands. "And, there is no better place than Marvel and Disney where Stan should be for his movies and theme park experiences. As we enter the centennial year of Stan's birthday, December 28, 2022, we are thrilled to see his memory and legacy will continue to delight fans through this new long-term agreement with Marvel." Under the terms of the deal, Marvel Studios has acquired rights to use Stan Lee's name, voice, likeness and signature in movies and television projects, as well as use images, existing footage and existing audio recordings featuring Stan. Exclusive rights to use Stan Lee's name, voice, likeness and signature in theme parks, water parks, cruise lines and in-park merchandise were included for Disney Parks, Experiences and Products as part of the deal.

08:33 EDT ChemoCentryx announces presentation on role of tunnels in HS - ChemoCentryx announced that a poster will be presented at the Society for Investigative Dermatology 2022 Annual Meeting, to be held May 18-21, 2022 in Portland, Oregon, that highlights unique immunological profiles of the subdermal tunnels in hidradenitis suppurativa, and how these profiles are differentiated with the stage of disease severity. The findings support the Company's plans to advance TAVNEOS into Phase III development for the treatment of patients with Hurley Stage III hidradenitis suppurativa. The poster titled, Spatial Transcriptomic Analysis of HS Skin Lesions Reveals that Tunnels are Immunologically Active and Activity Correlates with Disease Severity, will be presented as part of Poster/Exhibit Hall Session 2 on Friday, May 20 between 4:30 PM- 6:30 PM PT. Hidradenitis suppurativa is a chronic, disabling, inflammatory skin disease characterized by neutrophil-rich inflammatory nodules, abscesses, and tunnels. Complement dysregulation and neutrophil activation have been implicated in the pathogenesis of HS. The complement 5a receptor is highly expressed on neutrophils and is a major driver of the pro-inflammatory functions. Clinical assessment of the severity of HS includes staging using the Hurley system, where Hurley Stage III disease defines severe HS and Hurley Stage II denotes a more moderate disease presentation. At the SID 2022 Annual Meeting, ChemoCentryx will present data that show a marked increase in dermal inflammation in severe Hurley Stage III HS lesions compared to moderate Hurley II lesions. Genes for proinflammatory cytokines, chemokines, neutrophil activation factors, and B cells had higher expression in the severe compared to moderate HS lesions. The spatial gradients of cytokine and chemokine gene expression support the idea that more differentiated tunnels in Hurley III disease are intensely immunologically active, potentially contributing to ongoing active severe disease, rather than merely remnant structures of prior disease. TAVNEOS, a potent and specific inhibitor of human C5aR, was previously evaluated in the Phase II AURORA clinical trial in patients with moderate Hurley Stage II or severe Hurley Stage III HS. The data now presented at the SID meeting support and extend the Company's earlier findings showing increased presence of C5a- and C5aR-bearing cells in Hurley Stage III skin biopsies relative to Hurley II samples, and also provide further mechanistic evidence underpinning TAVNEOS's efficacy in patients with severe HS after 12 weeks of treatment in the AURORA trial. ChemoCentryx plans to meet with the FDA to discuss the Phase III development of TAVNEOS in patients with Hurley Stage III (severe) HS late in the second quarter, with the goal of initiating a Phase III clinical trial in those patients in the second half of 2022.

08:29 EDT 9 Meters Biopharma presents preclinical data on larazotide - 9 Meters Biopharma announced that Matthew Bryant, PharmD, Vice President of Medical Affairs at 9 Meters, delivered a poster presentation at the American Thoracic Society International Conference, taking place in San Francisco May 13 - 18, 2022. The presentation highlighted preclinical data investigating the use of larazotide, a tight junction regulator, to reduce lung fibrosis in an animal model of idiopathic pulmonary fibrosis. 9 Meters' is currently studying larazotide in a Phase 3 clinical trial for celiac disease. "IPF can be a truly devastating lung disease that results in lung injury and fibrosis, with no known cause," said Dr. Bryant. "We know that changes to the gut microbiome impacts immunopathology and may have a profound effect on lung diseases, and this crosstalk between the gut and lungs is referred to as the gut-lung axis. We look forward to continuing to learn more about the gut-lung axis in IPF, as our results have demonstrated that larazotide's effects on the gastrointestinal epithelial tight junctions may play an important role in reducing lung fibrosis and addressing symptoms of IPF." In the animal model of IPF, larazotide reduced pulmonary fibrosis as compared to controls and the reduction was found to be greater when larazotide was administered orally than when administered intratracheally. The authors concluded that larazotide's intestinal barrier-reinforcing activity may offer a clinical benefit in the treatment of IPF via the gut-lung axis.

08:20 EDT Purple Biotech announces initiation of Phase 2 study for CM24 - Purple Biotech (PPBT) announced the initiation of the Phase 2 portion of its ongoing study of CM24, a first-in-class monoclonal antibody with the potential to treat multiple cancers. The Phase 2 is an open-label, multicenter study in subjects with metastatic pancreatic cancer, PDAC, to evaluate the safety and tolerability of CM24 in combination with the PD-1 inhibitor Opdivo and chemotherapy. The primary study endpoint is to evaluate preliminary efficacy in 2nd line PDAC. The phase 2 portion of the study is being conducted as part of Purple Biotech's clinical collaboration with Bristol Myers Squibb (BMY). The companies together made the determination to prioritize PDAC over non-small cell lung cancer based on the positive interim data. Accordingly, this decision will allow an increase in the number of subjects that will be participating, and will accelerate this part of the study, and the updated timeline to complete this trial is within 2023. "We are thrilled at the progress being made to help move this treatment forward in the clinical trial process for the potential benefit of patients with pancreatic cancer," said Gil Efron, President and CFO of Purple Biotech. "We are thankful for our partners at BMS for collaborating with us on this study and their support. Importantly, the decision to prioritize the PDAC study will extend the cash runway of Purple Biotech through the end of 2024," added Efron.

08:20 EDT Target: Customers shifting spending to experiences from goods

08:18 EDT DMG Blockchain Solutions invests $1M in The INX Digital Company - DMG Blockchain Solutions announces a $1M strategic investment in The INX Digital Company, one of the world's first companies to receive FINRA clearance for trading security tokens, and the first to execute an SEC-registered IPO for a digital security made available to the general public. INX has launched a regulated digital asset trading ecosystem and is pioneering a new tokenized economy. DMG's investment in INX is a strategic initiative to promote institutional adoption of cryptocurrencies and blockchain technologies as well as accelerate the development of its Blockseer Core+ strategy. DMG believes that INX represents a multi-billion dollar opportunity as a front-runner in digital asset trading markets. INX is well-positioned to take significant market share as one of the top regulated trading platforms in the next five years. "DMG views this investment in INX as a furthering of its Core+ strategy to drive transaction revenue streams. Our INX partnership offers DMG the opportunity for Blockseer to add to its development roadmap the ability to offer customers new Blockseer-based products," said Sheldon Bennett, DMG's CEO.

08:18 EDT Applied Molecular Transport reducing workforce by 40% - Reducing workforce by approximately 40%, to 81 full-time employees, and focusing on execution of late-stage clinical trials and related CMC activities

08:17 EDT Green Plains announces aquafeed partnership with Riverence Group - Green Plains announced a partnership with the Riverence Group to form a joint venture to expand aquafeed production in Idaho. The venture will produce trout and salmon feeds for the Riverence Group, utilizing wholesome, sustainable ingredients including the 60%+ fermented protein product recently announced after the success of the development trial at Green Plains Wood River. "This partnership is yet another validation of our transformational path, creating a portfolio of innovative ingredients tailored to meet specific customer needs," said Todd Becker, President and Chief Executive Officer of Green Plains. "The Riverence Group is a highly respected aquaculture producer and we are eager to realize the value this collaboration brings to both partners. Using our low-carbon ingredients in Riverence's feeds can help them achieve their goal of using sustainable, domestically produced plant-based ingredients." As part of the joint venture, Green Plains contributed capital and supplied key ingredient services, while the Riverence Group contributed existing assets and a feed offtake agreement to support its own production, helping to meet the rapidly growing consumer demand from aquaculture in North America. The joint venture is anticipated to become operational in 2023.

08:16 EDT Applied Molecular Transport evaluating next steps for AMT-126 - Evaluating next steps for AMT-126, which recently demonstrated safety and tolerability in a Phase 1a trial in healthy volunteers

08:15 EDT Dentsply Sirona receives notice of filing delinquency from Nasdaq - DENTSPLY SIRONA received written notification from The NASDAQ Stock Market on May 12, 2022 that the Company is no longer in compliance with the Nasdaq Listing Rules since the Company has not yet filed its Quarterly Report on Form 10-Q for the period ended March 31, 2022. Nasdaq Listing Rule 5250(c)(1) requires Nasdaq-listed companies to timely file all periodic reports. This notice from Nasdaq has no immediate effect on the listing of the Company's common stock on the Nasdaq Global Market. As previously reported by the Company in its Notification of Late Filing on Form 12b-25, filed with the Securities and Exchange Commission on May 10, 2022, the Company was unable to file the 10-Q for the period ended March 31, 2022 within the prescribed period because the Company's Audit and Finance Committee, together with independent outside counsel, is conducting an investigation concerning the Company's use of incentives to sell products to distributors in the third and fourth quarters of 2021, whether those incentives were appropriately accounted for and whether the impact of those sales was adequately disclosed in the Company's periodic reports filed with the Commission. The Company expects to file the Quarterly Report as soon as practicable.

08:12 EDT Target CEO expects cost pressures to persist in coming quarters

08:11 EDT AIM ImmunoTech provides update on Ampligen long-COVID program - AIM ImmunoTech provided an update on its ongoing efforts to develop an effective therapeutic for "Long COVID" with its investigational drug, Ampligen. A Phase 3 prospective, double-blind, randomized, placebo-controlled trial of rintatolimod in ME/CFS produced objective improvement in exercise tolerance. An analysis of a subset of patients in that trial with early onset of symptoms showed a statistically significant 51.2% positive response. In an amendment to its ongoing, FDA-authorized AMP-511, AIM enrolled four post-COVID patients with new onset ME/CFS following acute COVID-19. Following at least 12 weeks of Ampligen treatment, each of these four patients indicated they had experienced a reduction in fatigue, as measured via Patient-Reported Outcomes questionnaires. A statistical analysis of these data indicated that the decrease in fatigue compared to baseline was statistically significant, despite the small number of patients. Based in part on these early positive data, AIM is working toward filing an Investigational New Drug application with the U.S. Food and Drug Administration for a Phase 2 study of Ampligen for the treatment of Post-COVID conditions. The newly planned IND is for 12 weeks of therapy. AIM CEO Thomas Equels stated: "While the recently published positive data in pancreatic cancer, advanced recurrent ovarian cancer and triple-negative breast cancer make Ampligen in oncology a top priority, we remain dedicated in our efforts to develop an effective therapy for ME/CFS and Long COVID. Millions of people have suffered too long from these debilitating conditions, and we are steadfast in our mission to help alleviate their suffering."

08:10 EDT Surrozen initiates dosing in Phase 1 trial of SZN-1326 - Surrozen announced that the first subject has been dosed in its three-part Phase 1 clinical trial to evaluate SZN-1326 for the potential treatment of moderate to severe ulcerative colitis. The trial initiation is approximately one quarter earlier than previously expected. Surrozen also recently announced the publication of an article by Surrozen scientists in the journal Cellular and Molecular Gastroenterology and Hepatology The results highlight the potential for this novel approach to treating inflammatory bowel disease. The Phase 1, randomized, placebo-controlled, single- and multiple-ascending-dose study will evaluate the safety, pharmacokinetics, and activity of SZN-1326. The first part of the trial will evaluate single doses of SZN-1326 via intravenous injection or infusion, or subcutaneous injection in healthy volunteers, progressing from 25 mg through 1500 mg. The second part will evaluate multiple ascending doses of SZN-1326 for a period of four weeks in healthy volunteers, with each subject assigned to one of three dose level cohorts increasing from 75 mg IV up to 750 mg IV. The primary endpoint of Parts 1 and 2 of the trial are safety and tolerability of SZN-1326 and secondary outcomes include pharmacokinetics as well as prevalence of Anti-Drug Antibodies. "The dosing of the first participant in our clinical study of SZN-1326 marks a significant milestone for Surrozen as we officially transition to a clinical-stage organization," said Craig Parker, President and Chief Executive Officer of Surrozen. "In addition, the trial marks a milestone in the advancement of Wnt signaling research, which plays an essential role in regulating many biological processes. I am proud of our team's advances in creating uniquely engineered antibodies that selectively modulate the Wnt pathway and their strong and timely execution in completing our preclinical package and initiating our clinical development program months earlier than planned. We look forward to continuing to build a broad discovery and clinical pipeline of Wnt antibodies to repair a broad range of tissues and organs damaged by serious disease."

08:09 EDT Target still seeing healthy spending by consumers, says CEO Cornell - Seeing stronger sales trends in recent weeks, says CEO Brian Cornell.

08:08 EDT HP Inc. reveals new gaming hardware, software - HP Inc. revealed its newest gaming hardware and software created for gamers everywhere with the thermally innovative OMEN 16 Laptop, accessible Victus 15 Laptop, and a variety of powerful updates to OMEN Gaming Hub to enable elevated gaming experiences for all. OMEN 16.1 Gaming Laptop PC expected to be available by this summer via HP.com and at Best Buy for a starting price of $1199.99 on HP.com. See local retailer for pricing. Victus 15.6 Gaming Laptop PC is expected to be available by this summer via HP.com and other retailers for a starting price of $799.99 on HP.com. See local retailer for pricing.

08:07 EDT Constellium, Morf3D enter joint additive manufacturing development program - Constellium (CSTM) is entering into an agreement with Morf3D to provide Aheadd CP1, one of its proprietary additive manufacturing, AM, powder solutions, to Morf3D, a subsidiary of Nikon Corporation (NINOY). "We are very excited to partner with Morf3D, a leading company in additive manufacturing, on the qualification and development of applications using our Aheadd CP1 aluminium powder," said Alireza Arbab, Head of Additive Manufacturing for Constellium. "Constellium recognized a gap in aluminium powder options for Laser Powder Bed Fusion and has developed new powders specifically for this AM process. We are confident that this program will highlight the benefits of Aheadd CP1 and help set new standards for aluminium component production using LPBF."

08:06 EDT CDK Global announces extension of expiration date of tender offers - CDK Global announced that it is extending the expiration date of each of its previously announced tender offers relating to any and all of its outstanding 4.500% Senior Notes due 2024, the interest rate of which adjusts from time to time and is currently 5.000%, 4.875% Senior Notes due 2027 and 5.250% Senior Notes due 2029 pursuant to its Offer to Purchase and Consent Solicitation Statement dated April 20, 2022. In conjunction with the Tender Offers, CDK solicited from holders of the Notes consents to the adoption of proposed amendments to the indentures governing the Notes to, among other things, eliminate any obligation to make a Change of Control Offer, substantially all of the other restrictive covenants and certain events of default and other provisions. The Expiration Date for each Tender Offer and Solicitation has been extended from 12:00 midnight, New York City time, at the end of the day on May 20, 2022 to 12:00 midnight, New York City time, at the end of the day on May 27, 2022. As of 5:00 p.m. New York City time, on May 17, 2022, holders of approximately 82.5%, 81.3% and 97.9% of the outstanding aggregate principal amount of the 2024 Notes, 2027 Notes and 2029 Notes, respectively, have validly tendered and not validly withdrawn their Notes. Previously tendered Notes may not be withdrawn. Except for the extension of the Expiration Date as described above, all other terms and conditions of each Tender Offer and Solicitation remain unchanged. Holders that have previously tendered their Notes do not need to re-tender their Notes or take any other action in response to this extension.

08:05 EDT Target facing 'multiple' cost pressures, says CEO Brian Cornell

08:05 EDT BlackBerry, Magna collaborate on ADAS solutions - BlackBerry (BB) and Magna International (MGA) have entered into a multi-year agreement to collaborate on various integrated Advanced Driver Assistance Systems solutions. As part of the agreement, BlackBerry will provide Magna with QNX software including the QNX Software Development Platform, QNX OS for Safety, QNX Platform for ADAS, as well as professional engineering services for system-level integration, performance optimization, and solution validation.

08:04 EDT iCAD announces new research supporting ProFound AI for DBT - iCAD announced that new research supporting ProFound AI for Digital Breast Tomosynthesis, DBT, will be presented at the Society of Breast Imaging, SBI/ACR, Breast Imaging Symposium, taking place May 16-19 in Savannah, GA. In an oral presentation today at 1:30 pm EDT, Colleen Madden, MD, FACR, Assistant Clinical Professor of Radiology at IUH Ball Memorial Hospital at Indiana University School of Medicine, will present promising findings from a retrospective study titled, "Real-World Breast Cancer Detection Before and After the Implementation of an Artificial Intelligence Detection System in a Digital Breast Tomosynthesis Screening Program." According to study findings, using ProFound AI in clinical practice with DBT, or 3D mammography, significantly enhanced radiologists' screening performance, improved cancer detection rates and reduced the rate of false positives. "This recent investigator initiated study confirms ProFound AI offers invaluable insight that helps radiologists to identify cancers more efficiently and accurately, which could dramatically improve outcomes for patients," said Stacey Stevens, President and CEO of iCAD. "iCAD is the only company to provide a complete portfolio of unrivaled1 AI solutions designed to help radiologists find cancers earlier, while reducing false positives and unnecessary patient recalls, which can cause unnecessary stress for a woman and her family."

08:03 EDT Aemetis signs six-year agreement with Trillium for renewable natural gas - Aemetis announced today that its Aemetis Biogas Services subsidiary has signed a six-year supply agreement with Trillium to provide an estimated 600,000 MMBtu of renewable natural gas to be used as transportation fuel in California. The RNG replaces up to the equivalent of 4.3 million gallons of diesel fuel, primarily used in heavy duty passenger and cargo vehicles. Aemetis completed Phase 1 of the Central Dairy Digester network in 2020 with two fully operational digesters and four miles of pipeline. The biogas from Phase 1 has been used as process energy at the Aemetis Keyes biorefinery to reduce the facility's dependency on petroleum-based natural gas and to decrease the carbon intensity of fuel ethanol produced. Phase 2 of the network consists of a centralized biogas upgrading facility, a utility gas pipeline interconnection unit, 10 dairy digesters and 32 miles of additional pipeline which are planned to be completed by Q4 2022. Aemetis plans to have more than 60 digesters built and operating by the end of 2026 which are designed to produce approximately 1.6 million MMBtu of RNG per year, displacing approximately 12.5 million gallons of diesel per year. Aemetis has completed construction and is currently commissioning the centralized gas cleanup facility and utility gas interconnect located at the Keyes Ethanol biorefinery where dairy biogas will be upgraded to RNG and injected into the utility pipeline through an interconnection with Pacific Gas and Electric. Upon receiving pathway certification from the California Air Resources Board, the fuel is scheduled to begin deliveries to Trillium in late 2022.

08:03 EDT Lilium announces 37 new patent applications published by EPO - Lilium announced 37 new patent applications, which have been published by the European Patent Office, EPO. These are engineering inventions for the core technology around the Lilium Jet, spanning several domains: Energy, Propulsion, Structures and Interior, Avionics and Custom Electric, with Lilium focusing more than 70% of its patents on Energy and Propulsion. Daniel Wiegand, Co-Founder and CEO of Lilium said: "We are excited that Lilium is creating and protecting the radical engineering innovations that make the Lilium Jet unique. The applications published today serve as a testament to our engineers' ingenuity and commitment to pushing the limits of technology and reinforcing Lilium's place at the forefront of eVTOL development. These patent filings move us one step closer to commercialization of the Lilium Jet, but they also stand to strengthen innovation in the aviation industry as a whole, with areas like energy needing constant investment in novel and sustainable systems and technologies."

08:00 EDT Franchise Group authorizes $500M stock repurchase program - Franchise Group announced that that its Board of Directors has approved a stock repurchase program under which the Company may repurchase up to $500M of its outstanding shares of common stock over the next three years.

07:50 EDT Surf Air Mobility to become public through Tuscan Holdings Corp. II combination - Surf Air Mobility and Tuscan Holdings Corp. II jointly announced that they have entered into a definitive business combination agreement resulting, subject to the satisfaction or waiver of certain closing conditions, in Surf Air Mobility becoming a publicly listed company. The acquisition of Southern, also announced, and the completion of the business combination with THCA positions SAM to be a leader in the electrification of commercial aviation, providing it with resources necessary to bring electrified powertrain technology to market and expanding and electrifying regional consumer scheduled and charter flight services. Following completion of the transactions, and the successful deployment of SAM's proprietary powertrain technology, SAM plans to deploy the world's largest fleet of hybrid electric aircraft on regional routes being serviced and on additional routes in new markets. SAM intends for its hybrid electric propulsion to reduce operating costs and reduce emissions from regional air travel by offering original equipment manufacturers and third-party operators the ability to upgrade existing aircraft to hybrid electric powertrains. SAM's agreements with AeroTEC and magniX will help the company accelerate the introduction of its proprietary electrification technology. magniX has successfully flown the world's largest fully-electric aircraft to date, a prototype Cessna Grand Caravan 208B, which it calls the eCaravan. SAM is designing its initial hybrid electric Cessna Grand Caravans to have the same flight range capabilities as their fully combustion counterparts, which will allow the company to utilize the hybrid electric Cessna Grand Caravan aircraft across its own existing network, connecting more airports with direct flights and building a regional mass transport platform to sustainably connect communities across the U.S. SAM also intends to make hybrid electric powertrain upgrades available to fleet owners on and off its consumer platform, as well as license its technology to OEMs for new aircraft types. The proposed transaction reflects an implied pro forma equity value of $1.42B, assuming full payment of earnout. The transaction is expected to provide up to $467M in gross cash proceeds to SAM, including committed capital from strategic and financial investors, as well as from THCA's cash in trust. The boards of directors of both SAM and THCA have unanimously approved the proposed business combination, which is expected to be completed in the second half of 2022, subject to, among other things, the approval by THCA's stockholders, satisfaction of the conditions stated in the definitive agreement and other customary closing conditions, including a registration statement being declared effective by the U.S. Securities and Exchange Commission, the receipt of certain regulatory approvals, and the receipt of required approvals to publicly list the securities of the combined company. The mergers are also conditioned on the closing of the acquisition of Southern. Although SAM and Southern are party to the Southern Agreement, there can be no assurance that the closing conditions set forth in the Southern Agreement will be satisfied and the acquisition will be completed.

07:44 EDT Farmland Partners acquires Illinois farm for $2.4M - Farmland Partners announced the closing of the acquisition of a 166-acre Illinois farm for $2.4M. The corn and soybean farm is located in Bureau County and includes a grain bin that can hold 16,000 bushels. FPI now owns 220 farms in the U.S. Corn Belt, spanning 44,700 acres that are leased to 36 tenants.

07:41 EDT Fabled Silver Gold amends Santa Maria option agreement with Golden Minerals - Fabled Silver Gold wishes to announce that it has amended the payment schedule on May 17, 2022 under its option agreement with Golden Minerals Company with respect to the Santa Maria Project. Pursuant to the terms of the terms of the amended Option Agreement, in order to acquire the Santa Maria Project, Fabled is now required make the final payment of $2,000,000 previously due on December 4, 2022 as follows: Option Payment Timing Payment Amount: December 4, 2022 $1,000,000; March 31, 2023 $250,000; June 30, 2023 $250,000; September 30, 2023 $250,000 December 31, 2023 $250,000. As consideration for the amendment Fabled will, on the date of the first payment mentioned above, issue to GMC that number of common shares of Fabled that are equal to a value of $75,000 at a price per share equal to the closing trading price of the Shares on the TSX Venture Exchange on the trading day immediately prior to the date that such payment is made. The terms of the amendment remain subject to the final approval of the TSXV. Share Issuance to Agora

07:38 EDT Morphic appoints Gibbons as SVP of Regulatory Affiars - Morphic Therapeutic (MORF) announced that Joanne Gibbons has been named Senior Vice President, SVP, of Regulatory Affairs. Gibbons was previously Vice President and Head of Regulatory Affairs at Codiak Biosciences (CDAK).

07:37 EDT Marimed awarded dispensary license in Ohio - MariMed announced it had been awarded a provisional dispensary license, PDL, by the Ohio Board of Pharmacy. MariMed won this license in the Ohio lottery process. The license allows the Company to develop a medical dispensary in Tiffin, Ohio, located south of Toledo and home to the University of Bucharest and Tiffin University. Under the Ohio regulations, MariMed must complete the buildout and pass final inspection by February of 2023. "We are delighted to enter the medical cannabis program in Ohio," said Bob Fireman, Chief Executive Officer of MariMed. "We intend to seek additional opportunities to expand our cannabis operations in Ohio including the distribution of our award-winning branded products."

07:36 EDT AeroClean provides resources to support government push for cleaner indoor air - AeroClean Technologies offers building owners and operators additional resources in navigating the National COVID-19 Preparedness Plan. The plan, presented by the Biden Administration to assist America in rebounding from the devastating effects wrought by the COVID-19 pandemic, provides a roadmap for fighting the virus with a multi-pronged approach focusing on four key goals, including: Protect Against & Treat COVID-19; Prepare For New Variants; Prevent Economic and Educational Shutdowns; and Continue To Vaccinate The World. The technology in the AeroClean Prgo systems uses hospital-grade HEPA filtration as well as optimized germicidal UV exposure to provide supplemental air cleaning and ventilation that removes and destroys 99.99% of harmful airborne pathogens, so businesses and organizations can meet the federal guidelines as suggested. "We are proud to provide our patented, germicidal UV-C LED technology, expertise, and commitment to helping Americans become more educated on indoor air quality and the resources available to them as they update their existing air filtration and ventilation systems," said Jason DiBona, CEO of AeroClean. "AeroClean Prgo air sanitization is a supplemental, real-time solution that directly answers the federal call to action regarding improving IAQ to help businesses, organizations, and schools better protect their workforce, customers, and students from the harmful effects of airborne pollutants and illness-causing pathogens, including COVID-19."

07:34 EDT Trump Media & Technology Group launches Truth Social Web App - Trump Media & Technology Group announced the launch of the Truth Social Web App, allowing all Americans to access Truth Social from any Internet-connected computer, phone, or device. The launch comes in advance of the originally anticipated May 31 target date.

07:34 EDT Acasti Pharma says PK bridging study of IV GTX-104 met all planned endpoints - Acasti Pharma announced today that the top line results of its pharmacokinetic bridging study with IV GTX-104, the Company's lead drug candidate for the treatment of Subarachnoid Hemorrhage, met all its planned study endpoints. The primary objective of the study was to evaluate the relative bioavailability of IV GTX-104 compared to oral nimodipine in healthy adult male and female subjects, while the secondary objective was to assess its safety and tolerability. The Company plans to submit these results to the US Food and Drug Administration, along with its proposed study design for the Phase 3 safety study which is on track to start in the second half of 2022. The safety study is expected to be the final step required to seek regulatory approval under the 505(b)(2) regulatory pathway before submitting a New Drug Application to the FDA. SAH affects about 50,000 patients per year in the U.S. and represents an estimated total addressable market of more than $300 million in the US alone. There are an estimated additional 55,000 patients in Europe. Based on the improved bioavailability, more convenient and consistent mode of administration, safety and tolerability, management believes GTX-104 has the potential to capture a significant share of the SAH market. The PK study was completed at a single center in Canada and followed a 2-period crossover design where each subject received IV GTX-104 first, followed by oral nimodipine; or oral nimodipine first, followed by IV GTX-104. Fifty-eight subjects were randomized in a ratio of 1:1 between IV GTX-104 first or oral nimodipine first. IV GTX-104 and oral nimodipine was administered to all subjects over a period of 72 hours. A total of 56 and 55 subjects were included in the PK analysis at Day 1 and Day 3, respectively, as two subjects did not complete one of the two periods and one subject was excluded due to a protocol deviation, as prospectively defined in the statistical analysis plan. The primary PK endpoints were maximum concentration during the first 4 hours on Day 1 and the total amount of nimodipine in the blood on Day 3. The secondary endpoint was Cmax measured over 24 hours on Day 3. The ratio of IV/oral is presented below for each endpoint with the corresponding 90% confidence interval. A ratio of 1 indicates no absolute difference between IV GTX-104 and oral nimodipine. The IV/oral rati and its corresponding 90% CI for the primary and secondary endpoints in the subjects who completed each treatment period were as follows: Day 1 Cmax, 0-4hr: 92%; AUC Day 3, 0-24hr: 106%; Day 3 Cmax, 0-24hr: 92%. All three endpoints indicated that statistically there was no difference in exposures between IV GTX-104 and oral nimodipine over the defined time periods for both maximum exposure and total exposure. Plasma concentrations obtained following IV administration showed significantly less variability between subjects as compared to oral administration of capsules, since IV administration is not as sensitive to some of the physiological processes that affect oral administration, such as taking the drug with and without meals, variable GI transit time, variable drug uptake from the GI tract into the systemic circulation, and variable hepatic blood flow and hepatic first pass metabolism. Previous studies have shown these processes significantly affect the oral bioavailability of nimodipine, and therefore cause oral administration to be prone to larger within and between-subject variability. The bioavailability of oral nimodipine capsules observed was only 8% compared to IV GTX-104. Consequently, less than one-tenth the amount of nimodipine is delivered with GTX-104 to achieve the same blood levels as with the oral capsules. In addition, the diurnal variation associated with IV GTX-104 was approximately half of that seen with the oral nimodipine capsules. Diurnal variation takes into consideration variation in body functions over the course of a day. No serious adverse events and no AEs leading to withdrawal were reported during the study. More gastro-intestinal disorders were observed with oral nimodipine, and as expected in the context of a phase I trial conducted in healthy volunteers, more administration and sampling site related events were observed with IV GTX-104. The other most frequently observed AEs were headache, somnolence and hot flashes/flushing.

07:32 EDT Diffusion Pharmaceuticals appoints Jaeger as CRO - Diffusion Pharmaceuticals (DFFN) announced that Raven Jaeger, M.S., has joined the Company as its Chief Regulatory Officer, CRO, effective immediately. Jaeger will be responsible for development and implementation of regulatory and related strategies to support the development and commercialization of Diffusion's product development candidates. Jaeger joins Diffusion from BridgeBio Pharma (BBIO) where she was most recently Senior Vice President, Regulatory Affairs.

07:26 EDT Parsons announces Parsons X approach - Parsons unveiled a new, central approach that unifies its digital organization and moves to a new delivery model that reinforces a data-driven focus to delivering digital-enabled solutions: Parsons X. The company said, "Parsons X enhances the company's decades of digital leadership while unlocking an enterprise approach that drives further efficiency, agility, and digital delivery into the critical infrastructure and national security markets. This unifying step for the company's digital offerings is focused on delivering innovative solutions to the world's most pressing challenges and opportunities. Critical infrastructure's digital revolution sparked the need for previously unthought of solutions - like cyber hardening and digital planning - that inevitably lead to the improved safety, security, sustainability, and efficiency of global society...Bringing together innovation from around Parsons, including state-of-the-art cyber solutions, federating data, artificial intelligence and machine learning, and digital twins, Parsons X is a digital accelerator designed to deliver faster, safer, more efficient, and more sustainable infrastructure and national security solutions to customers." While Parsons X extends throughout the enterprise, the inaugural innovation center of excellence will be in the company's PALADIN Lab on the U.S. Army's Aberdeen Proving Ground in Aberdeen, Md.

07:16 EDT Precision BioSciences publishes data from in vivo gene editing program - Precision BioSciences (DTIL) announced preclinical research from its ongoing in vivo gene editing program targeting hepatitis B virus, or HBV, has been published online in Molecular Therapy. Data from this study support the company's continued development of its PBGENE-HBV candidate as a promising gene editing approach that aims to eliminate virus persistence by targeting covalently closed circular DNA, or cccDNA, in patients with chronic hepatitis B. This study was conducted in collaboration with Gilead (GILD) and Acuitas Therapeutics and was also presented this week during the Gene Editing in Cancer and Complex Diseases oral session at the ASGCT Annual Meeting. Precision's gene editing program for chronic hepatitis B is designed to apply ARCUS to knock out persistent cccDNA and inactivate integrated hepatitis B genomes, potentially achieving durable HBsAg loss and functional cure. In this preclinical study, ARCUS efficiently targeted and degraded HBV cccDNA by 85% and reduced expression of HBsAg by 77% in HBV-infected PHH. Importantly, the optimized specificity of the ARCUS nuclease completely prevented detectable chromosomal translocations in the PHH model. To evaluate ARCUS in vivo, novel mouse and non-human primate models were developed that utilized an episomal adeno-associated virus containing a portion of the HBV genome to serve as a surrogate for cccDNA. After administration of LNP containing ARCUS mRNA, high on-target editing and a robust decrease in the cccDNA surrogate was observed in both episomal models, along with a durable 96% reduction of HBsAg in mice. Precision's in vivo development pipeline currently comprises six novel product candidates for genetic diseases. Three of these product candidates are wholly owned -- PBGENE-HBV for chronic hepatitis B, PBGENE-PH1 for primary hyperoxaluria type 1 and PBGENE-PCSK9 for familial hypercholesteremia -- and Precision expects to advance them to IND or CTA over the next three years.

07:12 EDT Cabaletta Bio presents updated interim DesCAARTes trial phase 1 data - Cabaletta Bio presented updated clinical and translational data through 6 months of follow-up in cohorts A1 through A3, safety data through 3 months and persistence data through 1 month of follow-up in cohorts A1 through A4 from the DesCAARTes trial at the American Society of Gene & Cell Therapy, ASGCT, 25th Annual Meeting being held in Washington, D.C. from May 16-19, 2022. Cabaletta's DesCAARTes Phase 1 trial is an open-label, dose escalation, multi-center study of DSG3-CAART in adults with mucosal-dominant pemphigus vulgaris. The trial is designed to determine the maximum tolerated dose of DSG3-CAART in adult subjects with active, anti-DSG3 Ab positive, biopsy confirmed mPV that is inadequately managed by one or more standard therapies. The primary endpoint is incidence of adverse events related to DSG3-CAART within three months of infusion. Secondary endpoints include CAART persistence, anti-DSG3 Ab levels and disease activity. The updated interim DesCAARTes trial Phase 1 data included 12 treated subjects, four cohorts with three patients per cohort; nine having completed six months follow up after DSG3-CAART infusion. The data show: No DLTs, CRS of any grade, or related serious AEs were observed in any subject within three months of DSG3-CAART infusion through cohort A4. There was a dose dependent increase in DSG3-CAART persistence through day 29 in cohorts A1 to A4, indicating that DSG3-CAART cells were not eliminated through immune-mediated rejection. Persistence in cohort A4 approached the lower end of the range that is observed in clinical trials of anti-CD19 CART combined with lymphodepletion in B-cell malignancies. In cohorts A1 to A3: Disease activity was clear or almost clear in 0/9 subjects at screening, 1/9 at pre-infusion, 2/9 at month one, 5/9 at month two, 3/9 at month three, 2/9 at month four, 3/9 at month five and 1/9 at month six after treatment. Through six months post DSG3-CAART infusion, no clear pattern was observed in changes in anti-DSG3 Ab levels or disease activity in the low dose cohorts where the A3 dose represents 6.7 to 10% of the ongoing cohort A5 dose. One subject from cohort A1 was retreated with 500 million cells and persistence in the subject was similar to the three subjects who were originally administered the cohort A3 dose, suggesting that there was not immune-mediated clearance of DSG3-CAART cells after retreatment and repeat dosing of patients is possible, if indicated. Data presented on the company's manufacturing process were as follows: In cohorts A1-A4, the manufacturing success rate was 100% with functional DSG3-CAART cells manufactured successfully from mPV patient apheresis material. Infused DSG3-CAART cells exhibited a stem cell or central memory phenotype with a strong positive correlation between the dose of gene modified T cells and post-infusion persistence to day 29. These data suggest that DSG3-CAART cells are not being eliminated by the pre-existing anti-DSG3 immunity present in mPV.

07:11 EDT Allego announces high power charging partnership with G&V Energy Group - Allego announced a partnership with G&V Energy Group, a Belgian company, active on the market of fuel stations with a focus on sustainability. G&V manages over 200 fuel stations under different brand names and operates 27 Breakpoint-shops. Allego and G&V Energy Group will enter a long-term high power charging partnership, to install Ultra-Fast Electric Vehicle charging stations at 100 fuel stations soon to become energy hubs throughout Belgium. 12 locations are due to be realized this calendar year, starting with the Noorderlaan in Antwerp. All 12 locations are co-financed by the European Union. Where possible the charging stations will be installed under the existing canopy of the fuel station itself, but as sites expand the installation of Allego canopies is also foreseen. The Electric Vehicle chargers themselves will be kitted in Allego branding for easy recognition for EV drivers. For the longer term with utilization increasing, there is the potential to expand to additional 150 locations. In Belgium, Allego currently operates a network of 5,000 public AC charging points covering more than 305 Flemish municipalities, in addition to 63 DC fast chargers located throughout all of Belgium. At present Allego is rolling out an additional 56 ultra-fast charging locations next to main highways in the coming year 2022-2023, upon completion this will make it the largest DC network in Belgium. In addition to these planned locations, the G&V Allego High power partnership announced today will add another 100 strategic locations in Belgium.

07:09 EDT Instil Bio to present novel TIL analytics at ASGCT - Instil Bio announced results of genomic and correlative analyses in a cohort of patients with metastatic melanoma treated with TILs manufactured by Instil. All TIL products were analyzed using T-cell receptor sequencing, RNA and protein expression, and correlated with patient demographic and historical treatment data. Results will be presented at an oral presentation at the American Society of Gene and Cell Therapy 25th Annual Meeting. In the presentation, a correlation between tumor response and clonal expansion of TILs is shown, as well as an inverse correlation between tumor response and specific T cell populations in the product. Expression profiling and transcriptional network analysis points to "master regulator" genes which can be manipulated during TIL manufacturing to enhance TIL activity.

07:08 EDT GH Research expects cash to fund operations into 2025 - The company said, "Cash was $270.8 million as of March 31, 2022, compared to $276.8 million as of December 31, 2021. We believe that our existing cash will be sufficient for us to fund our operating expenses and capital expenditure requirements into 2025."

07:07 EDT Ginkgo Bioworks and First Serv to co-develop biosecurity solutions in Qatar - Ginkgo Bioworks and First Serv, a Qatari investment holding company, have entered into a non-binding Memorandum of Understanding to develop and implement new biosecurity capabilities in Qatar. The initial goal of the partnership is to establish Doha as a critical node of a global pathogen monitoring network. Ginkgo, through its biosecurity and public health initiative, Concentric by Ginkgo, provides pathogen monitoring capabilities across thousands of sites including schools, airports, and other congregate settings. The network includes partnerships with laboratories, couriers, and healthcare providers. First Serv plans to develop critical infrastructure to detect emerging pathogens.

07:06 EDT Rubicon Organics says Delta Facility receives IMC-G.A.P. Certification - Rubicon Organics announced that its' Delta Facility has received its CUMCS Equivalency IMC-G.A.P. certification. Through the IMC-G.A.P. certification process, CU has declared that Rubicon Organics' dried cannabis products are compliant in accordance with the World Health Organization's guidelines on Good Agricultural Practices Medicinal Plants, the European Medicines Agency's, Guideline on GACP for Herbal Medical Products, and the Israeli Medical Cannabis GACP. Obtaining the Certification provides documented evidence that Rubicon Organics has met IMC-G.A.P.'s, WHO's and EMEA's strict standards for quality and consistency in the cultivation, harvest and primary processing of cannabis needed for export of cannabis inputs to certain jurisdictions, including Israel, Europe and Australia, for further processing into finished good via a GMP certified production facility.

07:04 EDT Axsome Therapeutics' AXS-05 shows antidepressant efficacy in Phase 2 trial - Axsome Therapeutics announced the publication of the results from the pivotal ASCEND Phase 2 clinical trial of AXS-05 in major depressive disorder - MDD -. AXS-05 is a novel, oral, investigational receptor antagonist with multimodal activity. The article was published in The American Journal of Psychiatry. The ASCEND trial assessed the efficacy and safety of AXS-05 versus the active comparator bupropion in patients with MDD. A total of 80 patients with a diagnosis of moderate to severe MDD were randomized to receive AXS-05 or bupropion for a total of 6 weeks. The primary endpoint was overall treatment effect. In the trial, AXS-05 demonstrated rapid, substantial, and statistically significant improvement in depressive symptoms and induction of remission compared with bupropion. Remission rates were significantly greater with AXS-05 at week 2 and every time point thereafter. Most secondary outcomes favored AXS-05. AXS-05 was generally well tolerated in the trial. The most common adverse events with AXS-05 were dizziness, nausea, dry mouth, decreased appetite, and anxiety. AXS-05 was not associated with psychotomimetic effects, weight gain, or sexual dysfunction.

06:59 EDT EU passenger car registrations down 20.6% in April - In April, new passenger car registrations in the European Union saw a significant drop of 20.6% as supply chain issues continued to weigh heavily on car production, according to the European Automobile Manufacturers Association. With the exception of the pandemic year in 2020, this was the weakest April result in terms of volumes sold since records began with 684,506 units sold, the group stated. All major markets contributed to the region's negative performance, with Italy down 33.0%, France down 22.6%, Germany down 21.5% and Spain down 12.1%, the group added. Publicly traded automakers include Daimler AG (DDAIF), Ford (F), General Motors (GM), Honda (HMC), Nissan (NSANY), Stellantis (STLA), Tesla (TSLA), Toyota (TM) and Volkswagen (VWAGY).

06:47 EDT Mednax appoints James Swift as COO, Curtis Pickert as Chief Physician Executive - Mednax named James Swift as COO and Curtis Pickert as Chief Physician Executive. Both Swift and Pickert have been with the company for over a decade and have held expanding leadership roles over that time. Swift joined Mednax in 2009 and most recently served as Executive VP and Chief Development Officer. Previously, he served as Regional President of the South Central Region for Pediatrix. Pickert joined Mednax in 2009 and most recently served as Executive VP, Clinical Services Division. Previously, he served as President of the Clinical Services Division, Chief Medical Officer of the Western Division, and Vice President, South Central Region for the company's Pediatrix Division.

06:46 EDT Target drops 22% to $167.51 after Q1 EPS misses estimates

06:42 EDT CMS Energy to add 300 megawatts of clean energy from two Michigan solar projects - Consumers Energy announced agreements to add 300 megawatts of clean energy - enough to power about 150,000 homes -- from two Michigan solar projects being developed in Genesee and Hillsdale counties. The solar developments are part of the company's Clean Energy Plan to increase renewable energy, eliminate coal electricity by 2025 and achieve net zero carbon emissions by 2040. Both projects are being developed by Ranger Power, a utility-scale solar development company based in Chicago. Consumers Energy would purchase power from Confluence Solar in Genesee County and Heartwood Solar in Hillsdale County. The agreements are being reviewed by the Michigan Public Service Commission. The new solar projects are each 150 megawatts and scheduled to begin operating by year-end 2024. Ranger Power will own and operate the sites.

06:35 EDT Dynatrace CFO Kevin Burns to leave at end of calendar year 2022 - Dynatrace announced that Kevin Burns, its CFO, will be leaving at the end of calendar year 2022. Dynatrace has initiated a search for a new CFO, and Burns will work to ensure a smooth transition of his duties once a new CFO is appointed.

06:24 EDT Golar LNG, Snam sign EUR 269M contract for LNG carrier - Snam and Golar LNG signed a contract through which Golar will deliver the existing LNG Carrier "Golar Arctic" as a floating storage and regasification unit, or FSRU, that Snam will install in the port area of Portovesme, in Sardinia, as part of a project to supply the island with energy. The contract, for a total consideration of 269M euros, includes the vessel and the capex for Golar to convert the Golar Arctic into an FSRU with storage capacity for up to 140,000 cubic meters. Further to the full conversion of the vessel, the FSRU will be sold to the Snam Group. Start of activities for the conversion of the ship into an FSRU and related fulfillments are subject to Snam's issuance of a Notice-to-Proceed and further to that the conversion is expected to take about two years for the Golar Arctic to be delivered.

06:10 EDT Homology Medicines presents results of gene editing candidate HMI-103 - Homology Medicines presented the mechanism of action and optimization of HMI-103, the nuclease-free gene editing candidate currently in a Phase 1 trial for phenylketonuria - PKU -. HMI-103 utilizes the body's natural DNA repair process to insert a functional copy of the PAH gene into a specific region of the genome. It is designed to provide a permanent DNA correction for PKU by replacing at least one disease-causing allele with a normal gene sequence in edited cells. Also at the American Society of Gene and Cell Therapy Annual Meeting, Homology presented data from its genome-wide integration assays, which confirmed the precision of HR-based integration of HMI-103, including no off-target editing in human hepatocytes in a humanized murine liver model. In addition, Homology shared new data from its GTx-mAb platform showing sustained antibody levels in murine and humanized models. The characterization of AAVHSC16 that has low tropism to the liver was also presented, a novel finding that provides opportunities to target additional diseases with a potentially lower immunogenicity profile. The company believes the new discovery that AAVHSC16 was able to target key tissues such as the CNS, muscle and cardiac tissue following a single I.V. administration, while having a very low affinity for the liver, may enable it to expand into new disease areas.

06:06 EDT Terran Orbital unit awarded contract from DARPA, terms not disclosed - Terran Orbital announced that its subsidiary, PredaSAR Corporation, received a contract award from the Defense Advanced Research Projects Agency under an Other Transaction Authority for Prototype Agreement. Specific terms of the Agreement were not disclosed.

06:05 EDT Tutor Perini unit awarded $85M United States Coast Guard contract - Tutor Perini announced that its subsidiary, Perini Management Services, has been awarded a task order valued at approximately $85M by the United States Coast Guard, for the design and construction of family housing at Nemetz Park Site, USCG Base Kodiak, in Kodiak, Alaska. The project scope of work includes construction of 50 family housing units in 25 duplex configurations. The project also includes demolition, utilities, roads, sidewalks, and other site improvements. The work will be phased to provide incremental turnover of units for beneficial occupancy. Work is expected to begin immediately with substantial completion anticipated in the third quarter of 2025. The contract value will be included in the company's second-quarter 2022 backlog.